↓ Skip to main content

A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma

Overview of attention for article published in Clinical Cancer Research, March 2022
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

blogs
1 blog
twitter
34 tweeters

Readers on

mendeley
4 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma
Published in
Clinical Cancer Research, March 2022
DOI 10.1158/1078-0432.ccr-22-0240
Pubmed ID
Authors

Michael J. Wagner, Yuzheng Zhang, Lee D. Cranmer, Elizabeth T. Loggers, Graeme Black, Sabrina McDonnell, Shannon Maxwell, Rylee Johnson, Roxanne Moore, Pedro Hermida de Viveiros, Lauri Aicher, Kimberly S. Smythe, Qianchuan He, Robin L. Jones, Seth M. Pollack

Twitter Demographics

The data shown below were collected from the profiles of 34 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 4 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 4 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 2 50%
Student > Ph. D. Student 1 25%
Unknown 1 25%
Readers by discipline Count As %
Unspecified 2 50%
Biochemistry, Genetics and Molecular Biology 1 25%
Unknown 1 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 30. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 July 2022.
All research outputs
#1,060,205
of 21,792,010 outputs
Outputs from Clinical Cancer Research
#730
of 12,337 outputs
Outputs of similar age
#23,631
of 341,463 outputs
Outputs of similar age from Clinical Cancer Research
#30
of 158 outputs
Altmetric has tracked 21,792,010 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,337 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,463 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 158 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.